Where does small cell lung cancer most commonly spread?

SCLC has a marked tendency to spread early. Common sites of metastasis include the brain, liver, bones and adrenal glands, although other sites can also be involved. Accurate staging before treatment begins is therefore particularly important.

Is molecular testing needed in the same way as in non-small cell lung cancer?

Usually not in the same way. In SCLC, there are currently no established oncogenic driver alterations that routinely determine standard treatment as they do in NSCLC. The treatment strategy is based mainly on disease stage, previous treatment and the patient's overall condition.

If treatment produces a very good or complete response, can the disease return?

Yes. SCLC is often highly sensitive to initial treatment, but it can later develop resistance and relapse. Structured follow-up after completion of initial treatment is therefore important.

What happens if small cell lung cancer relapses?

The next treatment depends substantially on the time elapsed since the previous treatment, the initial response and the patient's general condition. When relapse occurs after a longer interval, platinum-based treatment may be reused in selected patients, whereas in other situations a different systemic treatment is chosen.

Are there newer treatments for relapsed SCLC?

Yes. One important newer option is tarlatamab, an immunotherapeutic approach that engages T cells with cancer cells through DLL3. It has now been approved in the European Union for adults with extensive-stage SCLC who require systemic treatment after progression on or following first-line platinum-based therapy.

Can small cell lung cancer be treated with surgery?

Only in a very small proportion of patients with exceptionally early, localised disease and no lymph-node involvement. Even in these cases, surgery is not sufficient on its own and is followed by systemic treatment.

Small-Cell Lung Cancer (SCLC)

Diagnosis · Staging · Chemotherapy · Immunotherapy · Radiotherapy

Small-cell lung cancer (SCLC) is a distinct type of lung cancer with different biology and treatment from non-small-cell lung cancer. It is usually characterised by rapid growth and an early tendency to spread, but it may also show a substantial initial response to systemic treatment and radiotherapy.

The treatment strategy is determined primarily by the extent of the disease at diagnosis, the patient’s general condition and whether treatment with curative intent is feasible. The distinction between limited-stage and extensive-stage disease therefore remains particularly useful in everyday clinical practice.

What Needs to Be Known Before Treatment Is Selected?

Small-cell lung cancer may progress rapidly, but it is also often highly sensitive to initial chemotherapy. The patient’s general condition at diagnosis should therefore not be considered in isolation. When a patient’s poor condition is due mainly to the disease itself, there may be a meaningful possibility of an early response and clinical improvement after treatment begins.

Accurate staging is equally important, particularly whether the disease can be safely encompassed within a thoracic radiotherapy field with curative intent. In practice, this is the principal distinction between limited-stage and extensive-stage SCLC and directly influences how chemotherapy, immunotherapy and radiotherapy are combined. Brain imaging is also an essential part of the initial staging assessment.

How Is the Extent of the Disease Determined?

SCLC is now staged using the TNM system, as are other lung cancers. In everyday treatment planning, however, the distinction between limited-stage and extensive-stage SCLC remains particularly useful because it chiefly determines whether thoracic radiotherapy with curative intent is feasible. The ninth edition of TNM is the current anatomical staging system for lung cancer and has also been specifically validated for SCLC.

Limited-Stage SCLC

Disease is considered limited-stage when it is confined to the thorax and regional lymph nodes in a distribution that allows all known sites to be safely encompassed within an acceptable thoracic radiotherapy field with curative intent. In this setting, radiotherapy is a central part of treatment and is combined with systemic therapy.

Extensive-Stage SCLC

When distant metastases are present, or when the extent of thoracic disease cannot be safely encompassed within a curative radiotherapy field, the disease is classified as extensive-stage. Systemic treatment has the central role, although radiotherapy may still be used in selected cases for specific sites or as consolidative treatment.

Which Tests Are Required for Staging?

Initial staging includes contrast-enhanced CT of the chest and upper abdomen, together with brain imaging, preferably MRI. When the disease appears potentially limited-stage, FDG PET/CT may help identify sites not seen on conventional imaging and support more accurate radiotherapy planning.

How Is Limited-Stage SCLC Treated?

In limited-stage SCLC, treatment is usually given with curative intent. For most patients, it is based on a combination of chemotherapy and radiotherapy, generally administered concurrently.

Concurrent Chemotherapy and Radiotherapy

Radiotherapy is introduced early in treatment to achieve effective control of disease within the thorax, while chemotherapy also addresses possible microscopic disease beyond the radiotherapy field. When concurrent chemoradiotherapy is not feasible from the outset, the strategy is adapted according to the patient’s general condition and response.

Immunotherapy After Chemoradiotherapy

For patients who complete concurrent chemoradiotherapy without disease progression, immunotherapy follows, provided there are no contraindications.

Is There a Role for Surgery?

Surgery may be considered only in a very small proportion of patients with very early, localised disease and no lymph-node involvement. Even after complete resection, however, systemic treatment with platinum and etoposide follows.

How Is Extensive-Stage SCLC Treated?

In extensive-stage SCLC, systemic treatment has the central role. For most patients, first-line treatment includes chemotherapy combined with immunotherapy.

What Happens After the Initial Treatment Cycles?

If the disease does not progress, treatment continues with maintenance therapy. Immunotherapy remains a central part of this strategy, while other options are now also being evaluated.

What If the Patient Is Initially Very Unwell?

Poor general condition at diagnosis does not automatically preclude an active treatment approach. When the deterioration is due mainly to SCLC itself, chemotherapy may be started first and, if there is rapid clinical improvement, the possibility of adding immunotherapy can be reassessed. This is particularly relevant in SCLC because the initial response to treatment is often rapid.

Frequently Asked Questions

Scientific Sources & Clinical Guidelines

Khurshid H, Ismaila N, Bian J, et al. Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline. J Clin Oncol. 2023;41(35):5448–5472. doi:10.1200/JCO.23.01435. Kalemkerian GP, Khurshid H, Ismaila N. Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2025;43(1):101–105. doi:10.1200/JCO-24-02245. Daly ME, Ismaila N, Decker RH, et al. Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline. J Clin Oncol. 2021;39(8):931–939. doi:10.1200/JCO.20.03364. Cheng Y, Spigel DR, Cho BC, et al. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. N Engl J Med. 2024;391:1313–1327. doi:10.1056/NEJMoa2404873. Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379:2220–2229. doi:10.1056/NEJMoa1809064. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN). Lancet. 2019;394(10212):1929–1939. doi:10.1016/S0140-6736(19)32222-6. Paz-Ares L, Borghaei H, Liu SV, et al. Efficacy and Safety of First-Line Maintenance Therapy with Lurbinectedin plus Atezolizumab in Extensive-Stage Small-Cell Lung Cancer (IMforte). Lancet. 2025;405(10495):2129–2143. doi:10.1016/S0140-6736(25)01011-6. Mountzios G, Sun L, Cho BC, et al. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. N Engl J Med. 2025;393(4):349–361. doi:10.1056/NEJMoa2502099. European Medicines Agency. Imdylltra (tarlatamab): European Public Assessment Report. Marketing authorisation issued May 29, 2026. European Medicines Agency. Zepzelca (lurbinectedin): European Public Assessment Report. Indication in combination with atezolizumab as maintenance treatment for extensive-stage SCLC. Marketing authorisation issued May 29, 2026.

Contact

For appointment or contact information:

Contact & Appointments →

​Small-Cell Lung Cancer (SCLC)

​What Needs to Be Known Before Treatment Is Selected?

​How Is the Extent of the Disease Determined?

​Limited-Stage SCLC

​Extensive-Stage SCLC

​Which Tests Are Required for Staging?

​How Is Limited-Stage SCLC Treated?

​Concurrent Chemotherapy and Radiotherapy